Insulin and islet autoantibodies after pancreas transplantation
Summary Autoimmune recurrence and subsequent diabetes after pancreas transplantation has been described. In this cross‐sectional study 91 type 1 diabetic patients were examined after successful pancreas/kidney transplantation (SPK). We studied the prevalence of autoantibodies to insulin (IAA), gluta...
Gespeichert in:
| Veröffentlicht in: | Transplant international 2005-12, Vol.18 (12), p.1361-1365 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1365 |
|---|---|
| container_issue | 12 |
| container_start_page | 1361 |
| container_title | Transplant international |
| container_volume | 18 |
| creator | Dieterle, Christoph D. Hierl, Franz‐Xaver Gutt, Bodo Arbogast, Helmut Meier, Georg R. Veitenhansl, Martin Hoffmann, Johannes N. Landgraf, Rüdiger |
| description | Summary
Autoimmune recurrence and subsequent diabetes after pancreas transplantation has been described. In this cross‐sectional study 91 type 1 diabetic patients were examined after successful pancreas/kidney transplantation (SPK). We studied the prevalence of autoantibodies to insulin (IAA), glutamate decarboxylase (GAD) and tyrosine phosphatase (IA‐2) as well as parameters of pancreas graft function. Graft recipients were grouped according to immunoreactivity: group 1: no immunoreactivity; group 2: immunoreactivity to one antigen; group 3: immunoreactivity to two or three antigens. Twenty‐five percent of graft recipients displayed no immunoreactivity, 39% displayed positivity for one antigen and 36% were positive for two or three antigens. There were no significant differences concerning fasting glucose, HbA1c, glucose tolerance and renal function between the groups. Patients with cyclosporine (n = 42) as first‐line immunosuppression displayed more often immunoreactivity to IA‐2 and IAA than patients treated with tacrolimus (n = 49) (31% vs. 14%, P = 0.04; 67% vs. 47%, P = 0.04). In addition methylprednisolone therapy was related to less immunoreactivity to IA‐2. Immunological markers for type 1 diabetes can be determined in the majority of pancreas graft recipients despite adequate immunosuppression. However, immunoreactivity was not associated with impaired graft function. Patients with cyclosporine for immunosuppression and withdrawal of glucocorticoids therapy were more often immunoreactive to IAA and IA‐2. |
| doi_str_mv | 10.1111/j.1432-2277.2005.00223.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68817466</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68817466</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4233-b31f95d1b0cb708ada0b81c7e3fc2a2535ccb6b33a415164a0c19251b46efcd73</originalsourceid><addsrcrecordid>eNqNkG9LwzAQh4MoOqdfQYqg71ovSdO0IIiIfwYDQfR1uKQpZHTtTFqc397MDQVfeW_u4J47fjyEJBQyGutqkdGcs5QxKTMGIDIAxni23iOTn8U-mUDF8xRKmR-R4xAWEKlSwCE5ogWrJAgxITezLoyt6xLs6sSF1g4JjkOP3eB0XzsbEmwG65MVdsZbDMngsQurNgI4uL47IQcNtsGe7vqUvD3cv949pfPnx9nd7Tw1OeM81Zw2laipBqMllFgj6JIaaXljGDLBhTG60JxjTgUtcgRDKyaozgvbmFryKbnc_l35_n20YVBLF4xtYxDbj0EVZUllXhQRPP8DLvrRdzGbYrQSVQWURajcQsb3IXjbqJV3S_SfioLaGFYLtRGpNiLVxrD6NqzW8fRs93_US1v_Hu6URuBiB2Aw2DbRl3Hhl5NcgAQauest9-Fa-_nvAOr1ZRYH_gVFMZX8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219599012</pqid></control><display><type>article</type><title>Insulin and islet autoantibodies after pancreas transplantation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dieterle, Christoph D. ; Hierl, Franz‐Xaver ; Gutt, Bodo ; Arbogast, Helmut ; Meier, Georg R. ; Veitenhansl, Martin ; Hoffmann, Johannes N. ; Landgraf, Rüdiger</creator><creatorcontrib>Dieterle, Christoph D. ; Hierl, Franz‐Xaver ; Gutt, Bodo ; Arbogast, Helmut ; Meier, Georg R. ; Veitenhansl, Martin ; Hoffmann, Johannes N. ; Landgraf, Rüdiger</creatorcontrib><description>Summary
Autoimmune recurrence and subsequent diabetes after pancreas transplantation has been described. In this cross‐sectional study 91 type 1 diabetic patients were examined after successful pancreas/kidney transplantation (SPK). We studied the prevalence of autoantibodies to insulin (IAA), glutamate decarboxylase (GAD) and tyrosine phosphatase (IA‐2) as well as parameters of pancreas graft function. Graft recipients were grouped according to immunoreactivity: group 1: no immunoreactivity; group 2: immunoreactivity to one antigen; group 3: immunoreactivity to two or three antigens. Twenty‐five percent of graft recipients displayed no immunoreactivity, 39% displayed positivity for one antigen and 36% were positive for two or three antigens. There were no significant differences concerning fasting glucose, HbA1c, glucose tolerance and renal function between the groups. Patients with cyclosporine (n = 42) as first‐line immunosuppression displayed more often immunoreactivity to IA‐2 and IAA than patients treated with tacrolimus (n = 49) (31% vs. 14%, P = 0.04; 67% vs. 47%, P = 0.04). In addition methylprednisolone therapy was related to less immunoreactivity to IA‐2. Immunological markers for type 1 diabetes can be determined in the majority of pancreas graft recipients despite adequate immunosuppression. However, immunoreactivity was not associated with impaired graft function. Patients with cyclosporine for immunosuppression and withdrawal of glucocorticoids therapy were more often immunoreactive to IAA and IA‐2.</description><identifier>ISSN: 0934-0874</identifier><identifier>EISSN: 1432-2277</identifier><identifier>DOI: 10.1111/j.1432-2277.2005.00223.x</identifier><identifier>PMID: 16297055</identifier><language>eng</language><publisher>Oxford, UK: Munksgaard International Publishers</publisher><subject>Adult ; Autoantibodies - chemistry ; Autoimmune Diseases - diagnosis ; Biological and medical sciences ; Blood Glucose - metabolism ; Female ; General aspects ; Glucocorticoids - metabolism ; Glucose - metabolism ; Glucose Tolerance Test ; Glutamate Decarboxylase - immunology ; Graft Rejection ; Humans ; immunoreactivity ; immunosuppression ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Insulin - metabolism ; Islets of Langerhans - immunology ; islet‐antibodies ; Male ; Medical sciences ; Methylprednisolone - therapeutic use ; Middle Aged ; Models, Statistical ; Nephrology. Urinary tract diseases ; Pancreas - immunology ; pancreas transplantation ; Pancreas Transplantation - adverse effects ; Pancreas Transplantation - methods ; Pharmacology. Drug treatments ; Protein Tyrosine Phosphatase, Non-Receptor Type 1 ; Protein Tyrosine Phosphatases - chemistry ; Protein Tyrosine Phosphatases - immunology ; Recurrence ; Tacrolimus - pharmacology ; Time Factors ; Treatment Outcome</subject><ispartof>Transplant international, 2005-12, Vol.18 (12), p.1361-1365</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright Blackwell Publishing Ltd. Dec 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4233-b31f95d1b0cb708ada0b81c7e3fc2a2535ccb6b33a415164a0c19251b46efcd73</citedby><cites>FETCH-LOGICAL-c4233-b31f95d1b0cb708ada0b81c7e3fc2a2535ccb6b33a415164a0c19251b46efcd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1432-2277.2005.00223.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1432-2277.2005.00223.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17350701$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16297055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dieterle, Christoph D.</creatorcontrib><creatorcontrib>Hierl, Franz‐Xaver</creatorcontrib><creatorcontrib>Gutt, Bodo</creatorcontrib><creatorcontrib>Arbogast, Helmut</creatorcontrib><creatorcontrib>Meier, Georg R.</creatorcontrib><creatorcontrib>Veitenhansl, Martin</creatorcontrib><creatorcontrib>Hoffmann, Johannes N.</creatorcontrib><creatorcontrib>Landgraf, Rüdiger</creatorcontrib><title>Insulin and islet autoantibodies after pancreas transplantation</title><title>Transplant international</title><addtitle>Transpl Int</addtitle><description>Summary
Autoimmune recurrence and subsequent diabetes after pancreas transplantation has been described. In this cross‐sectional study 91 type 1 diabetic patients were examined after successful pancreas/kidney transplantation (SPK). We studied the prevalence of autoantibodies to insulin (IAA), glutamate decarboxylase (GAD) and tyrosine phosphatase (IA‐2) as well as parameters of pancreas graft function. Graft recipients were grouped according to immunoreactivity: group 1: no immunoreactivity; group 2: immunoreactivity to one antigen; group 3: immunoreactivity to two or three antigens. Twenty‐five percent of graft recipients displayed no immunoreactivity, 39% displayed positivity for one antigen and 36% were positive for two or three antigens. There were no significant differences concerning fasting glucose, HbA1c, glucose tolerance and renal function between the groups. Patients with cyclosporine (n = 42) as first‐line immunosuppression displayed more often immunoreactivity to IA‐2 and IAA than patients treated with tacrolimus (n = 49) (31% vs. 14%, P = 0.04; 67% vs. 47%, P = 0.04). In addition methylprednisolone therapy was related to less immunoreactivity to IA‐2. Immunological markers for type 1 diabetes can be determined in the majority of pancreas graft recipients despite adequate immunosuppression. However, immunoreactivity was not associated with impaired graft function. Patients with cyclosporine for immunosuppression and withdrawal of glucocorticoids therapy were more often immunoreactive to IAA and IA‐2.</description><subject>Adult</subject><subject>Autoantibodies - chemistry</subject><subject>Autoimmune Diseases - diagnosis</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Female</subject><subject>General aspects</subject><subject>Glucocorticoids - metabolism</subject><subject>Glucose - metabolism</subject><subject>Glucose Tolerance Test</subject><subject>Glutamate Decarboxylase - immunology</subject><subject>Graft Rejection</subject><subject>Humans</subject><subject>immunoreactivity</subject><subject>immunosuppression</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Insulin - metabolism</subject><subject>Islets of Langerhans - immunology</subject><subject>islet‐antibodies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pancreas - immunology</subject><subject>pancreas transplantation</subject><subject>Pancreas Transplantation - adverse effects</subject><subject>Pancreas Transplantation - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Tyrosine Phosphatase, Non-Receptor Type 1</subject><subject>Protein Tyrosine Phosphatases - chemistry</subject><subject>Protein Tyrosine Phosphatases - immunology</subject><subject>Recurrence</subject><subject>Tacrolimus - pharmacology</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0934-0874</issn><issn>1432-2277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkG9LwzAQh4MoOqdfQYqg71ovSdO0IIiIfwYDQfR1uKQpZHTtTFqc397MDQVfeW_u4J47fjyEJBQyGutqkdGcs5QxKTMGIDIAxni23iOTn8U-mUDF8xRKmR-R4xAWEKlSwCE5ogWrJAgxITezLoyt6xLs6sSF1g4JjkOP3eB0XzsbEmwG65MVdsZbDMngsQurNgI4uL47IQcNtsGe7vqUvD3cv949pfPnx9nd7Tw1OeM81Zw2laipBqMllFgj6JIaaXljGDLBhTG60JxjTgUtcgRDKyaozgvbmFryKbnc_l35_n20YVBLF4xtYxDbj0EVZUllXhQRPP8DLvrRdzGbYrQSVQWURajcQsb3IXjbqJV3S_SfioLaGFYLtRGpNiLVxrD6NqzW8fRs93_US1v_Hu6URuBiB2Aw2DbRl3Hhl5NcgAQauest9-Fa-_nvAOr1ZRYH_gVFMZX8</recordid><startdate>200512</startdate><enddate>200512</enddate><creator>Dieterle, Christoph D.</creator><creator>Hierl, Franz‐Xaver</creator><creator>Gutt, Bodo</creator><creator>Arbogast, Helmut</creator><creator>Meier, Georg R.</creator><creator>Veitenhansl, Martin</creator><creator>Hoffmann, Johannes N.</creator><creator>Landgraf, Rüdiger</creator><general>Munksgaard International Publishers</general><general>Blackwell Publishing</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200512</creationdate><title>Insulin and islet autoantibodies after pancreas transplantation</title><author>Dieterle, Christoph D. ; Hierl, Franz‐Xaver ; Gutt, Bodo ; Arbogast, Helmut ; Meier, Georg R. ; Veitenhansl, Martin ; Hoffmann, Johannes N. ; Landgraf, Rüdiger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4233-b31f95d1b0cb708ada0b81c7e3fc2a2535ccb6b33a415164a0c19251b46efcd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Autoantibodies - chemistry</topic><topic>Autoimmune Diseases - diagnosis</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Female</topic><topic>General aspects</topic><topic>Glucocorticoids - metabolism</topic><topic>Glucose - metabolism</topic><topic>Glucose Tolerance Test</topic><topic>Glutamate Decarboxylase - immunology</topic><topic>Graft Rejection</topic><topic>Humans</topic><topic>immunoreactivity</topic><topic>immunosuppression</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Insulin - metabolism</topic><topic>Islets of Langerhans - immunology</topic><topic>islet‐antibodies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pancreas - immunology</topic><topic>pancreas transplantation</topic><topic>Pancreas Transplantation - adverse effects</topic><topic>Pancreas Transplantation - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Tyrosine Phosphatase, Non-Receptor Type 1</topic><topic>Protein Tyrosine Phosphatases - chemistry</topic><topic>Protein Tyrosine Phosphatases - immunology</topic><topic>Recurrence</topic><topic>Tacrolimus - pharmacology</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dieterle, Christoph D.</creatorcontrib><creatorcontrib>Hierl, Franz‐Xaver</creatorcontrib><creatorcontrib>Gutt, Bodo</creatorcontrib><creatorcontrib>Arbogast, Helmut</creatorcontrib><creatorcontrib>Meier, Georg R.</creatorcontrib><creatorcontrib>Veitenhansl, Martin</creatorcontrib><creatorcontrib>Hoffmann, Johannes N.</creatorcontrib><creatorcontrib>Landgraf, Rüdiger</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplant international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dieterle, Christoph D.</au><au>Hierl, Franz‐Xaver</au><au>Gutt, Bodo</au><au>Arbogast, Helmut</au><au>Meier, Georg R.</au><au>Veitenhansl, Martin</au><au>Hoffmann, Johannes N.</au><au>Landgraf, Rüdiger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin and islet autoantibodies after pancreas transplantation</atitle><jtitle>Transplant international</jtitle><addtitle>Transpl Int</addtitle><date>2005-12</date><risdate>2005</risdate><volume>18</volume><issue>12</issue><spage>1361</spage><epage>1365</epage><pages>1361-1365</pages><issn>0934-0874</issn><eissn>1432-2277</eissn><abstract>Summary
Autoimmune recurrence and subsequent diabetes after pancreas transplantation has been described. In this cross‐sectional study 91 type 1 diabetic patients were examined after successful pancreas/kidney transplantation (SPK). We studied the prevalence of autoantibodies to insulin (IAA), glutamate decarboxylase (GAD) and tyrosine phosphatase (IA‐2) as well as parameters of pancreas graft function. Graft recipients were grouped according to immunoreactivity: group 1: no immunoreactivity; group 2: immunoreactivity to one antigen; group 3: immunoreactivity to two or three antigens. Twenty‐five percent of graft recipients displayed no immunoreactivity, 39% displayed positivity for one antigen and 36% were positive for two or three antigens. There were no significant differences concerning fasting glucose, HbA1c, glucose tolerance and renal function between the groups. Patients with cyclosporine (n = 42) as first‐line immunosuppression displayed more often immunoreactivity to IA‐2 and IAA than patients treated with tacrolimus (n = 49) (31% vs. 14%, P = 0.04; 67% vs. 47%, P = 0.04). In addition methylprednisolone therapy was related to less immunoreactivity to IA‐2. Immunological markers for type 1 diabetes can be determined in the majority of pancreas graft recipients despite adequate immunosuppression. However, immunoreactivity was not associated with impaired graft function. Patients with cyclosporine for immunosuppression and withdrawal of glucocorticoids therapy were more often immunoreactive to IAA and IA‐2.</abstract><cop>Oxford, UK</cop><pub>Munksgaard International Publishers</pub><pmid>16297055</pmid><doi>10.1111/j.1432-2277.2005.00223.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-0874 |
| ispartof | Transplant international, 2005-12, Vol.18 (12), p.1361-1365 |
| issn | 0934-0874 1432-2277 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68817466 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Autoantibodies - chemistry Autoimmune Diseases - diagnosis Biological and medical sciences Blood Glucose - metabolism Female General aspects Glucocorticoids - metabolism Glucose - metabolism Glucose Tolerance Test Glutamate Decarboxylase - immunology Graft Rejection Humans immunoreactivity immunosuppression Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Insulin - metabolism Islets of Langerhans - immunology islet‐antibodies Male Medical sciences Methylprednisolone - therapeutic use Middle Aged Models, Statistical Nephrology. Urinary tract diseases Pancreas - immunology pancreas transplantation Pancreas Transplantation - adverse effects Pancreas Transplantation - methods Pharmacology. Drug treatments Protein Tyrosine Phosphatase, Non-Receptor Type 1 Protein Tyrosine Phosphatases - chemistry Protein Tyrosine Phosphatases - immunology Recurrence Tacrolimus - pharmacology Time Factors Treatment Outcome |
| title | Insulin and islet autoantibodies after pancreas transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T06%3A32%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin%20and%20islet%20autoantibodies%20after%20pancreas%20transplantation&rft.jtitle=Transplant%20international&rft.au=Dieterle,%20Christoph%20D.&rft.date=2005-12&rft.volume=18&rft.issue=12&rft.spage=1361&rft.epage=1365&rft.pages=1361-1365&rft.issn=0934-0874&rft.eissn=1432-2277&rft_id=info:doi/10.1111/j.1432-2277.2005.00223.x&rft_dat=%3Cproquest_cross%3E68817466%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219599012&rft_id=info:pmid/16297055&rfr_iscdi=true |